Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: IFNα-Kinoid, Placebo, ISA 51 VG; Biological · Other
Lead sponsor: Neovacs; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more

Conditions: Pelvic Organ Prolapse
Interventions: Bupivacaine, Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Depression, Suicidal Ideation
Interventions: Ketamine, normal Saline; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Carcinoma, Hepatocellular
Interventions: Mapatumumab, Placebo, Sorafenib; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 9
States / cities: Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Conditions: Spinal Cord Injury
Interventions: Regular Insulin, 0.9 % Normal Saline; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Subjects
Interventions: 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion; Biological · Other
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neonatal Encephalopathy, Birth Asphyxia
Interventions: Normal saline placebo, Erythropoietin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 24 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection; Drug
Lead sponsor: Peter y. Liu; Other
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Schizophrenia
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Knee Osteoarthritis
Interventions: Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection; Procedure
Lead sponsor: Center For Interventional Pain and Spine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Exton, Pennsylvania

Conditions: Anterior Cruciate Ligament
Interventions: Gel-One, Saline Placebo; Drug · Other
Lead sponsor: Cale Jacobs, PhD; Other
Eligibility: 14 Years to 33 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetic Chronic Kidney Disease
Interventions: GCS-100, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Chula Vista, California • El Centro, California • La Jolla, California + 5 more

Conditions: Pain
Interventions: Hypertonic saline, Isotonic saline; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 20 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Human Metapneumovirus and Human Parainfluenza Infection
Interventions: mRNA-1653, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Omaha, Nebraska • Austin, Texas • Fort Worth, Texas

Conditions: Hypogammaglobulinemia, Congenital Heart Disease
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 6 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis of the Knee
Interventions: Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Des Plaines, Illinois

Conditions: Lactation
Interventions: Recombinant Human Prolactin, Recombinant human prolactin, Normal Saline; Drug · Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteo Arthritis Knee, Degenerative Joint Disease of Knee
Interventions: Autologous Adipose-Derived SVF (Stromal Vascular Fraction), Placebo; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Crohn's Disease
Interventions: Placebo, BMS-936557 (Anti-IP-10 Antibody); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 10
States / cities: Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more

Conditions: Calciphylaxis
Interventions: Sodium Thiosulfate, Placebo-Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Jacksonville, Florida • Chicago, Illinois • Maywood, Illinois + 9 more

Conditions: Obesity, Weight Loss
Interventions: Subcutaneous Placebo, Leptin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 19 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Encino, California • Newport Beach, California • San Diego, California + 7 more

Conditions: Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions: GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse

Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

High-dose Erythropoietin for Asphyxia and Encephalopathy

Hormonal Mechanisms of Sleep Restriction - Axis Study

Anti-Inflammatory Challenge in Schizophrenia

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Effects of Anticipation of Pain Relief on Brain Mechanisms

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Post-bypass Prophylactic IVIG in Infants and Neonates

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

Recombinant Human Prolactin for Lactation Induction

Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

Leptin in Human Energy and Neuroendocrine Homeostasis

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Bioenergetic Effects of Aging and Menopause (BEAM)